世界最新医学信息文摘（连续型电子期刊）
世界最新醫學信息文摘（連續型電子期刊）
세계최신의학신식문적（련속형전자기간）
World Latest Medicine Information
2015年
59期
10-11
,共2页
四联活菌肠溶胶囊%慢性腹泻%缓解时间%临床疗效%不良反应
四聯活菌腸溶膠囊%慢性腹瀉%緩解時間%臨床療效%不良反應
사련활균장용효낭%만성복사%완해시간%림상료효%불량반응
Tetravaccine enteric coated capsules%Chronic diarrhea%relief time%clinical effect%Adverse reaction
目的 探讨双歧杆菌、肠球茵、乳杆茵和芽孢杆茵四联活菌肠溶胶囊治疗慢性腹泻的疗效及安全性.方法 选取入医院治疗的慢性腹泻患者90例作为研究对象,采用数字随机法将患者分为对照组和观察组,对照组予以双歧三联活菌(含双歧杆菌、嗜酸乳菌、肠球菌)治疗,观察组予以四联活菌肠溶胶囊(含双歧杆菌、肠球茵、乳杆茵和芽孢杆茵)治疗,观察两组腹泻缓解时间、粪便形状,记录两组不良用药反应,评估临床疗效.结果 观察组治疗有效率为92.5%显著高于对照组75.0%,差异具有统计学意义(P<0.05).观察组治疗1~3d、11~14d腹泻改善几率分别为27.5%、92.5%显著高于对照组10.0%、75.0%;观察组治疗后大便成形、糊状便的几率分别为77.5%、47.5%显著高于对照组37.5%、25.0%,差异具有统计学意义(P<0.05).结论 双歧杆菌、肠球茵、乳杆茵和芽孢杆茵四联活菌肠溶胶囊治疗慢性腹泻疗效显著,且无明显不良反应,可临床推广使用.
目的 探討雙歧桿菌、腸毬茵、乳桿茵和芽孢桿茵四聯活菌腸溶膠囊治療慢性腹瀉的療效及安全性.方法 選取入醫院治療的慢性腹瀉患者90例作為研究對象,採用數字隨機法將患者分為對照組和觀察組,對照組予以雙歧三聯活菌(含雙歧桿菌、嗜痠乳菌、腸毬菌)治療,觀察組予以四聯活菌腸溶膠囊(含雙歧桿菌、腸毬茵、乳桿茵和芽孢桿茵)治療,觀察兩組腹瀉緩解時間、糞便形狀,記錄兩組不良用藥反應,評估臨床療效.結果 觀察組治療有效率為92.5%顯著高于對照組75.0%,差異具有統計學意義(P<0.05).觀察組治療1~3d、11~14d腹瀉改善幾率分彆為27.5%、92.5%顯著高于對照組10.0%、75.0%;觀察組治療後大便成形、糊狀便的幾率分彆為77.5%、47.5%顯著高于對照組37.5%、25.0%,差異具有統計學意義(P<0.05).結論 雙歧桿菌、腸毬茵、乳桿茵和芽孢桿茵四聯活菌腸溶膠囊治療慢性腹瀉療效顯著,且無明顯不良反應,可臨床推廣使用.
목적 탐토쌍기간균、장구인、유간인화아포간인사련활균장용효낭치료만성복사적료효급안전성.방법 선취입의원치료적만성복사환자90례작위연구대상,채용수자수궤법장환자분위대조조화관찰조,대조조여이쌍기삼련활균(함쌍기간균、기산유균、장구균)치료,관찰조여이사련활균장용효낭(함쌍기간균、장구인、유간인화아포간인)치료,관찰량조복사완해시간、분편형상,기록량조불량용약반응,평고림상료효.결과 관찰조치료유효솔위92.5%현저고우대조조75.0%,차이구유통계학의의(P<0.05).관찰조치료1~3d、11~14d복사개선궤솔분별위27.5%、92.5%현저고우대조조10.0%、75.0%;관찰조치료후대편성형、호상편적궤솔분별위77.5%、47.5%현저고우대조조37.5%、25.0%,차이구유통계학의의(P<0.05).결론 쌍기간균、장구인、유간인화아포간인사련활균장용효낭치료만성복사료효현저,차무명현불량반응,가림상추엄사용.
Objective To explore effect and safety analysis on chronic diarrhea treated by bifidobacterium, enterococcus, lactobacillus and bacillus tetravaccine enteric-coated capsules.Method choose 90 cases of patients with chronic diarrhea in our hospital as study objects, and by digital random method divide them into observation and control group. Control group was treated by Bifid Triple Viable (including Bifidobacterium, Acidophilus, Enterococcus), observation group by quadruple viable enteric capsules containing Bifidobacterium, Enterococcus, Lactobacillus and Bacillus), observe two groups with diarrhea relief time, stool shape, and record adverse medicine reaction of two groups and evaluate clinical effects.Result effective rate of observation group is 92.5%, which is significantly higher than control group (75.0%), and difference shows statistical significance(P<0.05). Improvement rate of observation group for 1-3d and 11-14d is 27.5% and 92.5% respectively, which are significantly higher than 10% and 75% of control group. Rate of bulky and pasty stool of observation group are 77.5% and 47.5% respectively, which were significantly higher than 37.5% and 25.0% of control group, and difference shows statistics meaning(P<0.05).Conclusion bifidobacterium, enterococcus, lactobacillus and bacillus tetravaccine enteric-coated capsules treating chronic diarrhea shows significant effects without obvious adverse reaction, it can be spreaded for clinical application.
